Appili Therapeutics Inc. (OTCMKTS:APLIF) Short Interest Update

Appili Therapeutics Inc. (OTCMKTS:APLIF) was the recipient of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 2,000 shares, a decline of 85.5% from the January 15th total of 13,800 shares. Based on an average trading volume of 57,000 shares, the days-to-cover ratio is currently 0.0 days.

Appili Therapeutics Stock Performance

APLIF stock opened at $0.02 on Thursday. The firm has a market cap of $2.78 million, a P/E ratio of -1.15 and a beta of -0.53. The firm’s fifty day moving average is $0.02 and its 200 day moving average is $0.03. Appili Therapeutics has a 52 week low of $0.01 and a 52 week high of $0.05.

Appili Therapeutics Company Profile

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.